Compare Gilead Sciences, Inc. (GILD) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Gilead Sciences, Inc. trades at $131.69 (market cap $163.51B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.82 (market cap $75.38B). The key difference: Gilead Sciences, Inc. is far larger — about 2.2× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.41%). Which is the better fit depends on your goals.
| GILD | MDLZ | |
|---|---|---|
Market Cap | $163.51B | $75.38B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $70.75 |
52-Week Low | $108.22 | $51.51 |
Enterprise Value | $178.05B | $95.47B |
Dividend Yield | 2.49% | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Mondelez International (MDLZ) trades at $60.48, up 2.86% with a bearish technical signal despite recent earnings beats. The company reported 2025 revenue of $38.54B with a net income margin of 6.64%, while valuation ratios like P/E of 29.07 suggest premium pricing. Analyst consensus is strongly bullish with a $68.00 price target, supported by innovation in brands like Oreo and Ritz. A dividend of $0.50 per share is scheduled for July 2026, enhancing income appeal amid stable cash flows.
Outlook remains positive due to consistent earnings outperformance and strategic brand initiatives, though risks include margin pressure from input costs and technical bearish indicators. The stock offers growth potential with a margin of safety from analyst targets, but investors should monitor Q2 2026 results on July 28 for volume growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
